The HHS wants to move oversight of the controversial drug discount program to the CMS, which has a more aggressive history ...

A federal judge ruled that the government did not violate the law in a dispute with J&J over the 340B drug discount program.

A federal court denied Johnson & Johnson's motion to implement a 340B drug rebate model, siding with HHS and hospitals who ...

The industry is awaiting guidance on a rebate approach to the contentious drug discount program for hospitals and aiming for tighter oversight.

Oklahoma lawmakers passed HB 2048 to protect the 340B Drug Pricing Program, overriding a veto amid growing pressure from pharmaceutical interests.

From relentless claim denials and payer pressures to policy debates around prior authorization and the 340B program, this mid-year briefing unpacks the six essential stories every revenue cycle leader ...

A U.S. District Court for the District of Columbia judge June 27 ruled against Johnson & Johnson and sided with the ...

Johnson & Johnson failed to convince a federal judge that the US government acted unlawfully when it rejected the company’s ...

Moderna disclosed that a study of 56,000 volunteers older than 50 found its new mRNA flu vaccine was more effective than an ...

A federal judge in D.C. recently ruled in favor of the U.S. Health Resources and Services Administration by finding that drug manufacturers must obtain pre-approval from HRSA before implementing ...

The U.S. District Court for the Middle District of Tennessee June 30 denied a motion for a preliminary injunction by AbbVie in its lawsuit against the state’s law on 340B pricing for contract pharmacy ...